In the neutropenic host, the impaired inflammatory response diminishes the signs and symptoms of pulmonary infection, making diagnosis difficult. A practical approach to diagnosis and treatment in this population is to assess the radiographic appearance of infiltrates as localized (occurring as early, refractory or late phase), or diffuse; this approach is reviewed here.
Introduction
Although radiation therapy, chemotherapy and bone marrow transplantation have dramatically improved the 'disease-free' survival for patients with cancer, the use of these treatments has resulted in an increase in morbidity and mortality due to infection. The single most important factor contributing to infections in the cancer patient is the degree of neutropenia ( 0.5 10 9 polymorphonuclear neutrophils (PMNs)/L), with patients having 0. 1 10 9 PMNs/L being at highest risk. 1 The duration of neutropenia also contributes significantly to the risk: prolonged granulocytopenia puts patients at significant risk of developing invasive fungal disease. 2 The neutropenic patient has increased vulnerability to pneumonia during the course of neutropenia for several reasons: alterations in normal flora; chemotherapy-and radiation-induced changes to the gastrointestinal and respiratory mucosa; increased risk of aspiration secondary to medications that alter consciousness; and therapyinduced vomiting. Owing to an impaired inflammatory response, signs and symptoms of pulmonary infection may be minimal in these patients who tend to have little or no cough and no sputum production or purulence. 3 Thus, the clinician must be alert to subtle signs of infection, and rapidly make a diagnosis and institute therapy even when pulmonary symptoms are minimal and only subtle abnormalities are present on chest X-ray. A practical approach to the diagnosis and management of pneumonia in the granulocytopenic patient is to consider radiographic appearance in terms of localized infiltrates (occurring in early, refractory and late phases) versus diffuse infiltrates (Table) . 
Localized pulmonary infiltrates

Early
Early pulmonary infiltrates occur concurrently with the first onset of fever in the neutropenic patient. The most common cause of early pneumonia in the neutropenic cancer patient is a bacterial process. Although pulmonary pathogens such as Haemophilus influenzae and Streptococcus pneumoniae need to be considered, the most probable responsible organisms are Klebsiella spp., other Enterobacteriaceae and Pseudomonas aeruginosa. 4 Staphylococcus aureus is also a likely pathogen in this population, given that pulmonary infection due to this organism now represents 20% of nosocomial pneumonias. 5 The diagnosis of early pneumonia with localized pulmonary infiltrates is most commonly based on relatively non-invasive tests. In addition to urine culture and two sets of blood cultures, sputum for Gram's stain and culture should be obtained, when possible. Induction of sputum with hypertonic saline nebulization may be the only means of obtaining a specimen in this population, as sputum production is frequently minimal. The diagnosis of bacterial pneumonia by sputum examination in neutropenic patients is particularly problematical, because the absence
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The diagnostic and therapeutic approach to lower respiratory tract infections in the neutropenic patient Table. Localized and diffuse pulmonary infiltrates in the granulocytopenic host: diagnostic approach, aetiological agents and treatment. Serial chest X-rays and, where appropriate, baseline and follow-up CT scans of focal infiltrates. c Granulocytopenic patients who have concomitant defective cell-mediated immunity or who are receiving corticosteroids are at particularly high risk for these infections. d Granulocytopenic patients with a previous episode of pulmonary aspergillosis have a high risk of developing recurrent pulmonary aspergillosis early in subsequent course of cytotoxic chemotherapy. e Granulocytopenic patients from endemic areas who have concomitant defective cell-mediated immunity or who are receiving corticosteroids are at particularly high risk for these infections.
f Pulmonary aspergillosis, trichosporonosis and fusariosis often develop in patients who are already receiving empirical amphotericin B (0.5 mg/kg/day); current studies indicate that these mycoses are more responsive to higher doses of amphotericin B (1.0-1.5 mg/kg/day). Although the role of flucytosine in pulmonary aspergillosis is controversial, we administer this compound to selected patients. g Amphotericin B is initiated for uncomplicated fungaemia in granulocytopenic patients at 0.5 mg/kg/day. However, several conditions warrant a higher dosage of amphotericin B (1.0 mg/kg/day): fungaemia developing during empirical amphotericin B; sustained fungaemia; fungaemia due to Candida tropicalis; or fungaemia plus proven end-organ infection. We also administer flucytosine for these conditions. of PMNs makes evaluation of the adequacy of the sputum specimen difficult. The criterion used by the US National Institutes of Health Clinic Center is that sputum specimens with 25 squamous cells per low power field are considered adequate and are forwarded for routine culturing. 6 Although modifications may be indicated when cultures become available, the initial treatment of early localized pneumonia is largely empirical. Therapy decisions should take into account known patterns of resistance within a given institution and, when available, information about the pathogens known to colonize an individual patient. The predominant Gram-positive and Gram-negative bacterial pathogens may be covered with a single antimicrobial agent (monotherapy) or with combination therapy. Traditionally, combination therapy has comprised an extended-spectrum penicillin such as carbenicillin, ticarcillin, mezlocillin or piperacillin and an aminoglycoside with or without a third, antistaphylococcal, drug. In patients for whom there is greater concern about nephrotoxicity, a double -lactam combination of an extended-spectrum penicillin and a third-generation cephalosporin with antipseudomonal activity (ceftazidime or cefaperazone) may be used. 2 Fluoroquinolones, aztreonam and piperacillin/tazobactam are other agents that may provide improved coverage of resistant Gramnegative bacilli and may also be used as part of combination therapy regimens. Monotherapy with ceftazidime, imipenem/cilastatin or meropenem has been studied extensively. These agents have an adequately broad spectrum of activity and sufficiently potent bactericidal activity to be used as empirical singleagent antimicrobial therapy in febrile granulocytopenic patients. [7] [8] [9] The use of ceftazidime alone, however, must be undertaken with caution, given the propensity for certain Enterobacteriaceae (e.g. Enterobacter, Citrobacter and Serratia spp.) to develop resistance due to inducible -lactamases during therapy. When these organisms are suspected or isolated from culture, it seems prudent to choose alternative therapy. 10 The addition of vancomycin to the initial empirical regimen may also be considered in patients known to be colonized with methicillin-resistant S. aureus and in institutions with a high prevalence of that organism.
Refractory
Refractory focal pulmonary infiltrates are defined by a lack of clinical response to empirical antibacterial therapy within 48-72 h. The reason for this may be infection by bacteria that are resistant to the initial antibiotic regimen, or by aetiological agents such as Legionella spp., Mycoplasma pneumoniae, Pneumocystis carinii, Aspergillus spp., Candida spp., Cryptococcus neoformans, Histoplasma capsulatum, Nocardia spp., Mycobacterium tuberculosis, atypical mycobacterial species, herpesviruses or helminthic infections, especially Strongyloides stercoralis. 2 Non-infectious causes of pulmonary infiltrates must also be considered; these include radiation pneumonitis, congestive heart failure, chemotherapy-related drug toxicity, pulmonary haemorrhage, tumour or emboli, progression of underlying malignancy and adult respiratory distress syndrome. 4 Invasive procedures should not be undertaken without considering the need to support a patient who may be thrombocytopenic and who may also have a coagulopathy. However, it is frequently necessary to consider invasive diagnostic procedures such as bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial biopsy, transthoracic needle aspiration or open lung biopsy in patients with refractory disease. In this patient population, BAL is associated with fewer complications such as haemorrhage or pneumothorax and is a reasonable initial intervention.
2 Specimens obtained by BAL should be sent for: Gram's stain; special stains for P. carinii, mycobacteria, fungi, herpes simplex virus (HSV) and cytomegalovirus (CMV); direct fluorescent antibody for Legionella spp.; cytology; routine culture (including charcoal yeast extract agar for legionella); and culture for acid-fast bacilli, fungal pathogens and selected viruses. If BAL is non-diagnostic, the risk of more invasive procedures must be weighed against their clinical benefit; this is an area of ongoing controversy in the literature. One study, from the US National Cancer Institute, compared transthoracic needle aspiration, transbronchial biopsy and open lung biopsy in each of 17 granulocytopenic patients with pulmonary infiltrates. The diagnostic yields were 30%, 59% and 94%, respectively. 11 Other studies have found open lung biopsy to be of more limited use in directing medical therapy and influencing clinical outcome. 12 In general, if open lung biopsy is to be performed, it should be undertaken early in the disease course, before prolonged empirical antimicrobial therapy and significant clinical deterioration. 4 Modifications in antimicrobial therapy should, whenever possible, be guided by the results of invasive diagnostic testing. However, if the patient's condition precludes the use of bronchoscopy or open lung biopsy, further empirical changes that should be considered include: modification of the antibacterial regimen to include expanded therapy for resistant Gram-negative and Grampositive bacteria; introduction of erythromycin therapy with or without rifampicin (to provide empirical coverage for pathogens such as legionellae and mycoplasmas); and addition of co-trimoxazole (as empirical therapy for P. carinii and Nocardia spp.). 2 
Late
Late pulmonary infiltrates occur on or after the seventh day of empirical antimicrobial therapy in granulocyto-penic patients. Although resistant bacterial pathogens remain a consideration, invasive fungal disease, especially that caused by Aspergillus spp., becomes more likely. 2 Pulmonary infection with Candida spp. (due either to haematogenous pulmonary candidiasis or candida bronchopneumonia) also deserves careful consideration. 13 Other mycoses, less commonly encountered but still of significant pathogenic potential in the neutropenic host, include Trichosporon beigelii, Fusarium spp. and the Zygomycetes. 2 Although the diagnosis of invasive fungal disease requires histological confirmation, non-invasive respiratory and surveillance cultures revealing Aspergillus spp. and Fusarium spp. have been highly correlated with the development of invasive disease in studies based on autopsy findings.
14 If amphotericin B therapy (1.0-1.5 mg/kg iv daily) has not already been started, such positive culture results should prompt its institution with or without the addition of flucytosine, which has been shown to be beneficial in animal models 15 and in limited clinical trials. 16 If routine respiratory cultures for fungi are negative, more invasive diagnostic measures should be undertaken. BAL may prove diagnostic and is a reasonable initial diagnostic tool, but the absence of fungal isolates from BAL specimens does not preclude a fungal aetiology in many patients. 17, 18 In this instance, open lung biopsy should be performed, since it may deliver valuable information that both prevents the empirical use of highdose amphotericin B with its attendant risk of nephrotoxicity, and provides a specific diagnosis to guide therapy. 2 In the patient who cannot tolerate an invasive procedure because of either severe thrombocytopenia or a likely inability to survive the procedure itself, a CT scan of the chest may be helpful. In patients with pulmonary aspergilloma, CT scanning of the chest may reveal a 'crescent sign' (a solid mass surrounded by a crescent of air which moves when the patient is moved from the prone to the supine position), 19, 20 constituting evidence on which to base a presumptive diagnosis of invasive pulmonary fungal disease.
Once a diagnosis has been made, therapy can be tailored to the pathogen. Appropriate therapy for invasive disease secondary to aspergillus has already been mentioned. The role of itraconazole in the treatment of invasive aspergillosis awaits further evaluation; in-vitro data and anecdotal reports suggest it may prove beneficial. 21, 22 For the persistently febrile neutropenic patient in whom antibacterial therapy has failed and who is to be treated presumptively for fungal disease, the mainstay of therapy remains amphotericin B. Although fluconazole given prophylactically at the initiation of chemotherapy has been shown to reduce morbidity and mortality in patients with chemotherapy-induced neutropenia, 23, 24 evidence to date does not support its use for the empirical treatment of suspected invasive fungal disease in this population. 25 
Diffuse pulmonary infiltrates
If diffuse infiltrates are present on chest X-ray or CT scan, non-infectious causes become more likely and should be more heavily weighted in the differential diagnosis. Of the infectious causes, P. carinii, Legionella spp., M. pneumoniae and CMV are most likely. Infections caused by Streptococcus mitis, mycobacteria, varicella-zoster virus (VZV), HSV, influenza A, respiratory syncytial virus and S. stercoralis should also be considered. 2 Given the virulence of the microbial pathogens encountered in the neutropenic patient with diffuse pulmonary infiltrates, some investigators suggest the early use of invasive procedures to obtain a diagnosis. 4 As a minimum, bronchoscopy with BAL should be done (with the addition of transbronchial biopsy, if feasible); the specimens obtained should be processed as described above. If the diagnosis is not established by less invasive means, an open lung biopsy should be considered.
When bronchoscopy and open lung biopsy are absolutely contraindicated, empirical antimicrobial therapy should include co-trimoxazole and erythromycin with or without rifampicin to cover P. carinii and Legionella spp. If there is appropriate epidemiological evidence of S. stercoralis infection, or if it has been identified by histology, the therapy of choice is thiabendazole. The decision to use empirical antiviral therapy must be made on an individual basis. Although CMV pneumonitis is a common occurrence in the bone marrow transplant population, it usually occurs after the neutropenic period. However, if invasive CMV disease is diagnosed, combination therapy with intravenous ganciclovir and intravenous immunoglobulin is the treatment of choice. 20 VZV pneumonia is likely if the patient with pulmonary infiltrates has skin lesions characteristic of either chickenpox or herpes zoster; optimal therapy remains high-dose intravenous acyclovir. 20 
